We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+31.25%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.67B
AUM Growth
+$753M
Cap. Flow
-$209M
Cap. Flow %
-7.82%
Top 10 Hldgs %
54.38%
Holding
380
New
93
Increased
88
Reduced
106
Closed
73

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.1M
2
CYTR
CytRx Corp
CYTR
+$5.67M
3
CELG
Celgene Corp
CELG
+$4.08M
4
UTHR icon
United Therapeutics
UTHR
+$3.38M
5
DVAX
Dynavax Technologies
DVAX
+$3.33M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$7.47M
2
ABT icon
Abbott
ABT
+$6.5M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$4.84M
4
NVIV
InVivo Therapeutics Holdings Corp
NVIV
+$3.87M
5
AMGN icon
Amgen
AMGN
+$3.54M

Sector Composition

Rank Sector Weight
1 Healthcare 9.24%
2 Consumer Staples 0.04%
3 Technology 0.03%
4 Industrials 0.01%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
26
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$21.1M 0.79%
5,850
+4,224
+260% +$90.6K
BIIB icon
27
CALL
Biogen
BIIB
$30.9B
$20.9M 0.78%
667
-1,199
-64% -$355K
ESRX
28
CALL
DELISTED
Express Scripts Holding Company
ESRX
$20.4M 0.77%
+2,897
New +$217K
BMY icon
29
PUT
Bristol-Myers Squibb
BMY
$129B
$18.7M 0.7%
+3,469
New +$223K
VRTX icon
30
CALL
Vertex Pharmaceuticals
VRTX
$123B
$17.1M 0.64%
1,955
+1,346
+221% +$127K
CEMP
31
PUT
DELISTED
Cempra, Inc.
CEMP
$15.3M 0.57%
6,323
+3,983
+170% +$85.7K
TVTX icon
32
CALL
Travere Therapeutics
TVTX
$5.17B
$14.1M 0.53%
6,293
-3,152
-33% -$60K
PBYI icon
33
CALL
Puma Biotechnology
PBYI
$398M
$13.6M 0.51%
2,021
+1,563
+341% +$79K
SHPG
34
CALL
DELISTED
Shire pic
SHPG
$13.5M 0.51%
698
– –
SHPG
35
PUT
DELISTED
Shire pic
SHPG
$13.5M 0.51%
698
– –
XNTK icon
36
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.94B
$13M 0.49%
1,958
+100
+5% +$5.75K
UTHR icon
37
PUT
United Therapeutics
UTHR
$26.1B
$13M 0.49%
+1,098
New +$132K
HUM icon
38
PUT
Humana
HUM
$43.9B
$12.4M 0.46%
+700
New +$121K
ESRX
39
PUT
DELISTED
Express Scripts Holding Company
ESRX
$11.9M 0.45%
+1,691
New +$126K
AZN icon
40
CALL
AstraZeneca
AZN
$269B
$11.6M 0.43%
+1,760
New +$115K
LXRX icon
41
CALL
Lexicon Pharmaceuticals
LXRX
$1.03B
$11.3M 0.42%
6,263
+943
+18% +$15.2K
HES
42
CALL
DELISTED
Hess
HES
$11M 0.41%
+2,059
New +$110K
ASRT
43
CALL
DELISTED
Assertio
ASRT
$10.8M 0.4%
72
+59
+454% +$74.1K
VTRS icon
44
CALL
Viatris
VTRS
$20.8B
$10.7M 0.4%
2,804
– –
DVAX
45
CALL
DELISTED
Dynavax Technologies
DVAX
$10.5M 0.39%
9,984
-728
-7% -$10.5K
ALNY icon
46
CALL
Alnylam Pharmaceuticals
ALNY
$38.3B
$9.81M 0.37%
1,448
+461
+47% +$32.5K
OTLK icon
47
Outlook Therapeutics
OTLK
$187M
$9.64M 0.36%
14,179
+1,248
+10% +$793K
BLUE
48
CALL
DELISTED
bluebird bio
BLUE
$9.35M 0.35%
+107
New +$77.5K
BMY icon
49
Bristol-Myers Squibb
BMY
$129B
$8.46M 0.32%
+156,887
New +$10.1M
DVAX
50
PUT
DELISTED
Dynavax Technologies
DVAX
$8M 0.3%
7,628
+1,686
+28% +$24.2K
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sabby Management held 380 positions worth $2.67B, up 39% from $1.92B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sabby Management withdrew a net $209M in Q3 2016, closing 73 positions and reducing 106 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $4.84M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, down from 13% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Sabby Management opened a new position in Bristol-Myers Squibb worth $8.46M.

  • Sabby Management's largest Q3 2016 buy was Bristol-Myers Squibb: 156,887 shares worth $8.46M.
  • Sabby Management added most to Dynavax Technologies in Q3 2016, an estimated $3.33M increase.
  • Sabby Management's biggest Q3 2016 reduction was Sarepta Therapeutics, cutting an estimated $7.47M.
  • Sabby Management fully exited Global Blood Therapeutics, Inc. in Q3 2016, selling an estimated $4.84M.
  • Sabby Management's ten largest holdings make up 54% of its $2.67B portfolio in Q3 2016.
  • Sabby Management opened 93 new positions and closed 73 in Q3 2016.
  • Sabby Management's portfolio value rose 39% quarter-over-quarter to $2.67B.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.